MEN 16132, a novel potent and selective nonpeptide antagonist for the human bradykinin B2 receptor. In vitro pharmacology and molecular characterization. Eur J Pharmacol. 2005, 528(1-3): 7-16.

In vivo metabolite detection and identification in drug discovery via LC-MS/MS with data-dependent scanning and postacquisition data mining. J Mass. Spectrom. 2005, 40(12): 1572-82.

Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anticancer Drugs. 2005, 16(10): 1083-9.

Sabarubicin (MEN 10755) and paclitaxel show different kinetics in nuclear factor-kappaB (NF-kB) activation: effect of parthenolide on their cytotoxicity. Anticancer Res. 2005 25(3B): 2119-28.

NF-kappaB activation contributes to anthracycline resistance pathway in human ovarian carcinoma cell line A2780. Int J Oncol. 2005, 27(3):799-806.

MEN 16132, a novel potent and selective nonpeptide kinin B2 receptor antagonist: in vivo activity on bradykinin-induced bronchoconstriction and nasal mucosa microvascular leakage in anesthetized guinea pigs. J Pharmacol. Exp. Ther. 2005 315(2):616-23.

Pharmacology of an original and selective nonpeptide antagonist ligand for the human tachykinin NK2 receptor. Eur J Pharmacol. 2005, 516(2): 104-11

A novel continuous subcutaneous lactate monitoring system. Biosens Bioelectron. 2005, 20(11): 2244-50.

Involvement of nitric oxide in both central and peripheral haemodynamic effect of D/L-nebivolol and its enantiomers in rats. Eur J Pharmacol. 2005, 511(2-3): 167-74.

Pharmacological investigation of hydrogen sulfide (H2S) contractile activity in rat detrusor muscle. Eur J Pharmacol. 2005, 509(2-3): 171-7

CHASE, a charge-assisted sequencing algorithm for automated homology-based protein identifications with matrix-assisted laser desorption/ionization time-of-light post-source decay fragmentation data. J Mass Spectrom. 2005, 40(4): 475-88.

Generation of a new class of hNK(2) receptor ligands using the “fragment approach”. Bioorg Med Chem. Lett. 2005, 15(3): 585-8.

Antioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res. 2005, 33(1): 42-54.

A phase II study of sabarubicin (MEN 10755) as a second line therapy in patients with locally advanced or metastatic platinum/taxane resistant ovarian cancer. Invest New Drugs 2005, 23(1): 85-9.

Urotensi-II receptor ligands. From agonist to antagonist activity. J Med Chem. 2005, 48(23): 7290-7.

Inhibition of nitric oxide synthesis blocks the inhibitory response to capsaicin in intestinal circular muscle preparations from different species. Life Sci. 2005, 76(24): 2773-82.

Tachykinins and tachykinin receptors: effects in the genitourinary tract. Life Sci. 2005, 76(8): 835-62.